Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers

Introduction. The increase in the incidence of whooping cough in children and adults of different age groups justifies the need for their revaccination and the development of new, acceptable for these purposes. This work is devoted to substantiating the design of a clinical trial and describing the results of a comparative study of the safety and tolerability of the drug "GamLPV" with two-fold intranasal administration to healthy adult volunteers using two methods. The choice of the scheme and method of administration of the drug is justified. The serological structure of the population of adults aged 18–40 years living in Moscow and the Moscow region is characterized.

Aim. Determination of the safety and tolerability of the drug with a double intranasal administration of the vaccine by drip method and spraying through an actuator.

Materials and methods. A randomized placebo-controlled trial included 50 healthy male and female volunteers aged 18 to 40 years who met the inclusion criteria. The volunteers were divided into 2 groups of 25 people: a drip method of administration and spraying through an "actuator". By both methods, the drug was administered twice with an interval of 60 days.

Results and discussion. Serological analysis of the population of healthy volunteers at the prescreening stage justified the inclusion in the study of volunteers containing anti-pertussis antibodies in the blood (IgG ≤40 Ed/ml). A comparison of the results of preclinical studies on an experimental model of non-human monkeys and the first phase of a clinical study of GamLPV allowed us to propose two methods of double administration of the drug as a promising vaccination scheme for volunteers. A comparative randomized study shows the safety of using the proposed scheme for vaccination of adult volunteers.

Conclusions. Both proposed methods of double administration can be used to plan a multicenter study to research the immunogenicity and protective activity of GamLPV.

1. Kilgore P. E., Salim A. M., Zervos M. J., Schmittd H.-J. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clinical Microbiology Reviews. 2016;29(3):449–486. DOI: 10.1128/CMR.00083-15.

2. Wiley K. E., Zuo Y., Macartney K. K., McIntyre P. B. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine. 2013;31(4):618–625. DOI: 10.1016/j.vaccine.2012.11.052.

3. Wendelboe A. M., Njamkepo E., Bourillon A., Floret D. D., Gaudelus J., Gerber M., Grimprel E., Greenberg D., Halperin S., Liese J., Muñoz-Rivas F., Teyssou R., Guiso N., Van Rie A. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293–299. DOI: 10.10097/01.inf.0000258699.64164.6d.

4. Medkova A. Yu., Alyapkina Yu. S., Sinyashina L. N. Amelina I. P., Alekseev Ya. I., Karataev G. I., Bokovoy A. G. The prevalence of subclinical forms of pertussis and analysis of phase states of bacteria Bordetella pertussis. Children infections. 2010;4:19–22. (In Russ.)

5. Salim A. M., Liang Y., Kilgore P. E., Protecting Newborns Against Pertussis: Treatment and Prevention Strategies. Pediatr Drugs. 2015;17:425–441. DOI: 10.1007/s40272-015-0149-x.

6. Kandeil W., van den Ende C., Bunge E. M., Jenkins V. A., Ceregido M. A., Guignard A. Guignard. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Review of Vaccines. 2020.19(7):621–638. DOI: 10.1080/14760584.2020.1791092.

7. Warfel J. M., Zimmerman L. I., Merkel T. J. Acellular Pertussis Vaccines Protect Against Disease But Fail to Prevent Infection and Transmission in a Nonhuman Primate Model. Proc Natl Acad Sci USA. 2014;111:787–792. DOI: 10.1073/pnas.1314688110.

8. Wilk M. M., Borkner L., Misiak A., Curham L., Allen A. C., Mills K. H. G. Immunization With Whole Cell But Not Acellular Pertussis Vaccines Primes CD4 TRM Cells That Sustain Protective Immunity Against Nasal Colonization With Bordetella Pertussis. Emerg Microbes Infect. 2019;8:169–85. DOI: 10.1080/22221751.2018.1564630.

9. Holubová J., Stanek O., Brazdilova L., Masin J., Bumba L., Gorringe A. R., Alexander F., Sebo P. Acellular Pertussis Vaccine Inhibits Bordetella Pertussis Clearance From the Nasal Mucosa of Mice. Vaccines. 2020;8(4):695. DOI: 10.3390/vaccines8040695.

10. Dubois V., Chatagnon J., Thiriard A., Bauderlique-Le Roy H., Debrie A.-S., Coutte L, Locht C. Suppression of Mucosal Th17 Memory Responses by Acellular Pertussis Vaccines Enhances Nasal Bordetella Pertussis Carriage. NPJ Vaccines. 2021;6(1). DOI: 10.1038/s41541-020-00270-8.

11. Medkova A. Yu., Sinyashina L. N., Amichba A. A., Semin E. G., Shevtsova Z. V., Matua A. Z., Djidaryan A. A., Kubrava D. T., Kondzhariya I. G., Barkaya V. S., Mikvabiya Z. Ya., Karataev G. I. Preclinical studies of safety, immunogenicity and protective activity of attenuated Bordetella pertussis bacteria on the Macaca mulatta model. Journal of microbiology, epidemiology and immunobiology. 2020;97(4):312–323. (In Russ.) DOI: 10.36233/0372-9311-2020-97-4-3.

12. Medkova A. Yu., Lidzhieva A. A., Semin E. G., Sinyashina L. N., Sioundioukova R. A., Dyakov I. N., Kolobukhina L. V., Kruzhkova I. S., Merkulova L. N., Rusanova M. G., Antipyat N. A., Smetanina S. V., Karataev G. I. A clinical study of the safety and tolerability of live nasal vaccines for the prevention of pertussis. Drug development & registration. 2021;10(1):114–119. (In Russ.) DOI: 10.33380/2305-2066-2021-10-1-114-119

13. Medkova A. Yu., Lidzhiyeva A. A., Semin E. G., Sinyashina L. N., Syundyukova R. A., Snegireva N. A., Chernyshova I. N., Gavrilova M. V., Bushkova K. K., Kolobukhina L. V., Kruzhkova I. S., Merkulova L. N., Rusanova M. G., Dyakov I. N., Karatayev G. I. Immunogenicity of the drug "Live intranasal vaccine for the prevention of pertussis" (GamLPV) with a single use in healthy volunteers. Journal of microbiology, epidemiology and immunobiology. 2021;98(6):706–720. (In Russ.) DOI: 10.36233/0372-9311-194.

14. Glanc S. Primer of biostatistics. Moscow: Praktika; 1998. 459 p. (In Russ.)

15. Basov A. A., Tsvirkun O. V., Gerasimova A. G., Rossoshanskaya N. V., Babenko V. N. Condition of Specific Immunity to Pertussis in Different Age Groups of Children. Epidemiology and Vaccinal Prevention. 2015;14(3):84–88. (In Russ.) DOI: 10.31631/2073-3046-2015-14-3-84-88.

16. Berbers G., van Gageldonk P., van de Kassteele J., Wiedermann U., Desombere I., Dalby T., Toubiana J., Tsiodras S., Ferencz I. P., Mullan K., Griskevicius A., Kolupajeva T., Vestrheim D. F., Palminha P., Popovici O., Wehlin L., Kastrin T., Maďarová L., Campbell H., Ködmön C., Bacci S., Barkoff A.-M., He Q. Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries. Nature Communications. 2021;12(1):2871. DOI: 10.1038/s41467-021-23114-y.